EXAS vs SXT · rev $2.76B vs P/E 33, rev $1.61B
EXACT Sciences Corporation (EXAS) versus Sensient Technologies Corporation (SXT) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Sensient Technologies Corporation (SXT) is a specialty chemicals company listed on NYSE.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
Latest reported SXT revenue for 2025-12-31 was $1.61B. Net income was $134.5M. Revenue was up 3.5% from 2024-12-31 to 2025-12-31. SXT currently screens at market cap $4.73B and trailing P/E 32.9.
EXAS currently screens at market cap $20.03B. SXT currently screens at market cap $4.73B and trailing P/E 32.9.
Not investment advice. Open the EXAS and SXT stock pages for the full models.
Not investment advice.